Not Signed In -
Travoprost |
Travatan |
Clinical Trial: A 6-week safety and efficacy study of Travatan compared to Xalcom in subjects with open-angle glaucoma(OAG) or ocular hypertension(OHT)
This study is currently recruiting patients.
|
Purpose
To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Glaucoma, Open-Angle Ocular Hypertension | Drug: Travoprost (0.004%) Drug: Latanoprost (0.005%)/Timolol (0.5%) | Phase IV |
MedlinePlus related topics: Eye Diseases; Glaucoma
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A 6-week safety and efficacy study of TRAVATAN compared to XALCOM in subjects with open-angle glaucoma or ocular hypertension.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.
Location and Contact Information
Alcon Clinical +1-817-568-6747 IntlDev@alconlabs.com
Europe, ; Recruiting
More Information
Study ID Numbers: C-01-74
Record last reviewed: January 2003
Last Updated: January 6, 2003
Record first received: January 3, 2003
ClinicalTrials.gov Identifier: NCT00051155
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: January 2003
Last Updated: January 6, 2003
Record first received: January 3, 2003
ClinicalTrials.gov Identifier: NCT00051155
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
Resources
- Travatan (Drug Digest)
- Travatan Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
